Skip To Content
BuzzFeed News Home Reporting To You

After Trump's Tweet, The Government Is Funding A Coronavirus Study Of Hydroxychloroquine

A North Carolina company won a $750,000 deal days after the president’s controversial statements about the antimalarial drugs.

Posted on March 28, 2020, at 4:13 p.m. ET

Mandel Ngan / Getty Images

The journalists at BuzzFeed News are proud to bring you trustworthy and relevant reporting about the coronavirus. To help keep this news free, become a member and sign up for our newsletter, Outbreak Today.


The US government awarded a North Carolina pharmaceutical company $750,000 to do research on antimalarial drugs days after President Donald Trump praised the medicines as a possible treatment for COVID-19.

Pharmaceutical Product Development (PPD) is supposed to conduct a one-month study on the use of "hydrochloroquine and chloroquine in patients with coronavirus disease (COVID-19), positive for SARS-COV-2 virus exposure, or pre-exposure and post-exposure prophylaxis,” according to federal contracting records.

Chloroquine and hydroxychloroquine attracted attention earlier this month after a French study involving 42 COVID-19 patients indicated that a small number treated with the drugs — which were developed for use against malaria, but also taken by patients with lupus or rheumatoid arthritis — showed positive results.

At a White House press conference three days after the French study appeared, Trump said “we’re going to be able to make that drug available almost immediately.” Two days later, the president tweeted that a combination of chloroquine and another drug “have a real chance to be one of the biggest game changes in the history of medicine.”

HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine. The FDA has moved mountains - Thank You! Hopefully they will BOTH (H works better with A, International Journal of Antimicrobial Agents).....

The Food and Drug Administration urged caution, however, and said officials are still trying “to determine whether it can be used to treat patients with mild-to-moderate COVID-19 to potentially reduce the duration of symptoms, as well as viral shedding, which can help prevent the spread of disease.” The World Health Organization agreed that further tests should be conducted, but many scientists criticized Trump’s comments as being overzealous and said the French study was flawed.

Nevertheless, demand for the drugs skyrocketed, leading to a shortage for patients who were taking it for other conditions. The drugs drew widespread exposure from Fox News and Elon Musk.

Do you have questions you want answered? You can always get in touch. And if you're someone who is seeing the impact of this firsthand, we’d also love to hear from you. Reach out to us via one of our tip line channels at tips.buzzfeed.com

The chloroquine study is one of many emergency contracts related to the coronavirus outbreak struck by the US government, which has marshaled some of its enormous purchasing power to enter into similar agreements for hospital beds, protective equipment, and other supplies. Federal contracting data show that 16 agencies have spent more than $250 million on COVID-19 measures since January.

PPD has until April 21 to finish its work, according to the terms of the purchase order. Information about the agreement was posted on a website that lists government contracts. BuzzFeed News has filed a Freedom of Information Act request to obtain a copy of it. The deal was first reported by the Daily Beast.

Within the Department of Health and Human Services, the assistant secretary for preparedness and response has awarded 25 contracts worth more than $210 million since January.

The largest of those went to 3M to produce N95 masks. That $173 million contract runs until October 2021. Rapid Deployment Inc., an Alabama emergency response company, received $28 million for “support services.”

Founded in 1985, PPD is now a global giant with 23,000 employees and offices in 46 countries. The company did not respond to detailed messages seeking comment about its coronavirus research, nor did officials from HHS.

According to the company’s website, it is currently working on about 80 active projects for the Department of Defense, National Institutes of Health, Biomedical Advanced Research and Development Authority (BARDA), and other federal agencies. Under its contract with BARDA, PPD “supports the design and conduct of clinical studies to develop medical countermeasures to protect against bioterrorism, pandemic influenza and other public health emergencies.”

Since 2000, PPD has been awarded more than $700 million in government contracts. The company has also performed work for the Department of Homeland Security, NASA, and the Agency for International Development.

On Jan. 27, PPD announced it was going public. In its first earnings call with investors on March 5, three weeks before its arrangement with HHS, the chair and chief executive, David Simmons, discussed how the pandemic had affected business in China and what PPD was doing to contain the spread of the virus. The outbreak had impacted “the ability of our employees to visit hospitals and other clinical trial sites to conduct monitoring visits,” its earnings report said.


  • Picture of Jason Leopold

    Jason Leopold is a senior investigative reporter for BuzzFeed News and is based in Los Angeles. He is a 2018 Pulitzer finalist for international reporting, recipient of the IRE 2016 FOI award and a 2016 Newseum Institute National Freedom of Information Hall of Fame inductee.

    Contact Jason Leopold at jason.leopold@buzzfeed.com.

    Got a confidential tip? Submit it here.

  • Picture of Anthony Cormier

    Anthony Cormier is an investigative reporter for BuzzFeed News and is based in New York. While working for the Tampa Bay Times, Cormier won the 2016 Pulitzer Prize for Investigative Reporting.

    Contact Anthony Cormier at anthony.cormier@buzzfeed.com.

  • Picture of John Templon

    John Templon is a data reporter for BuzzFeed News and is based in New York. His secure PGP fingerprint is 2FF6 89D6 9606 812D 5663 C7CE 2DFF BE75 55E5 DF99

    Contact John Templon at john.templon@buzzfeed.com.

ADVERTISEMENT